Targeted gene expression profiling in Leishmania braziliensis and Leishmania guyanensis parasites isolated from Brazilian patients with different antimonial treatment outcomes

Infection, Genetics and Evolution

Volumn 10, Issue 6, 2010, Pages 727-733

  Torres, Davi Coe ^a   Adaui, Vanessa ^b,c   Ribeiro Alves, Marcelo ^a   Romero, Gustavo A S ^d   Arévalo, Jorge ^b   Cupolillo, Elisa ^a   Dujardin, Jean Claude ^c  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b INSTITUTO DE MEDICINA TROPICAL ALEXANDER VON HUMBOLDT   (Peru)

^c INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^d UNIVERSITY OF BRASILIA   (Brazil)

Author keywords

Cutaneous leishmaniasis; Leishmania braziliensis; Leishmania guyanensis; Targeted gene expression profiling; Treatment failure

Indexed keywords

ABC THIOL TRANSPORTER; ABC TRANSPORTER; AQUAGLYCEROPORIN; GENE PRODUCT; GLUTAMATE CYSTEINE LIGASE; GLUTATHIONE SYNTHASE; MEGLUMINE ANTIMONATE; PROTEIN MRPA; RNA; THIOL DEPENDENT REDUCTASE 1; TRYPANOTHIONE REDUCTASE; UNCLASSIFIED DRUG; ANTIMONY; ANTIPROTOZOAL AGENT; MEGLUMINE; MEGLUMINE ANTIMONIATE; ORGANOMETALLIC COMPOUND;

ARTICLE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GROWTH CURVE; HUMAN; LEISHMANIA; LEISHMANIA BRAZILIENSIS; PARASITE ISOLATION; PHENOTYPE; PRIORITY JOURNAL; PROMASTIGOTE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SKIN LEISHMANIASIS; TREATMENT OUTCOME; ANIMAL; BRAZIL; COMPARATIVE STUDY; DRUG RESISTANCE; GENETICS; ISOLATION AND PURIFICATION; LEISHMANIASIS, CUTANEOUS; PARASITE; PARASITOLOGY;

ANIMALS; ANTIMONY; ANTIPROTOZOAL AGENTS; BRAZIL; DRUG RESISTANCE; GENE EXPRESSION PROFILING; HUMANS; LEISHMANIA BRAZILIENSIS; LEISHMANIA GUYANENSIS; LEISHMANIASIS, CUTANEOUS; MEGLUMINE; ORGANOMETALLIC COMPOUNDS; PARASITES; TREATMENT OUTCOME;

LEISHMANIA BRAZILIENSIS; LEISHMANIA GUYANENSIS;

EID: 77954028485     PISSN: 15671348     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.meegid.2010.05.006     Document Type: Article

References (46)

1. Akopyants N.S., Matlib R.S., Bukanova E.N., Smeds M.R., Brownstein B.H., Stormo G.D., Beverley S.M. Expression profiling using random genomic DNA microarrays identifies differentially expressed genes associated with three major developmental stages of the protozoan parasite Leishmania major. Mol. Biochem. Parasitol. 2004, 136:71-86.
2. Allen S., Neal R.A. The in vitro susceptibility of macrophages infected with amastigotes of Leishmania spp. to pentavalent antimonial drugs and other compounds with special relevance to cutaneous isolates. Leishmaniasis 1989, 711-720. Plenum Press, New York. D.T. Hart (Ed.).
3. Arevalo J., Ramirez L., Adaui V., Zimic M., Tulliano G., Miranda-Verástegui C., Lazo M., Loayza-Muro R., De Doncker S., Maurer A., Chappuis F., Dujardin J.C., Llanos-Cuentas A. Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis. J. Infect. Dis. 2007, 195:1846-1851.
4. Ashford R., Desjeux P., Deraadt P. Estimation of population at risk of infection and number of cases of Leishmaniasis. Parasitol. Today 1992, 8:104-105.
5. Azeredo-Coutinho R.B., Mendonça S.C., Callahan H., Portal A.C., Max G. Sensitivity of Leishmania braziliensis promastigotes to meglumine antimoniate (glucantime) is higher than that of other Leishmania species and correlates with response to therapy in American tegumentary leishmaniasis. J. Parasitol. 2007, 93:688-693.
6. Bermúdez H., Rojas E., Garcia L., Desjeux P., Dujardin J.C., Boelaert M., Chappuis F. Generic sodium stibogluconate is as safe and effective as branded meglumine antimoniate, for the treatment of tegumentary leishmaniasis in Isiboro Secure Park, Bolivia. Ann. Trop. Med. Parasitol. 2006, 100:591-600.
7. Carter K.C., Hutchison S., Henriquez F.L., Légaré D., Ouellette M., Roberts C.W., Mullen A.B. Resistance of Leishmania donovani to sodium stibogluconate is related to the expression of host and parasite (gamma)-glutamylcysteine synthetase. Antimicrob. Agents Chemother. 2006, 50:88-95.
8. Cohen-Freue G., Holzer T.R., Forney J.D., McMaster W.R. Global gene expression in Leishmania. Int. J. Parasitol. 2007, 37:1077-1086.
9. Croft S.L., Sundar S., Fairlamb A.H. Drug resistance in leishmaniasis. Clin. Microbiol. Rev. 2006, 19:111-126.
10. Cupolillo E., Momen H., Grimaldi G. Genetic diversity in natural populations of New World Leishmania. Mem. Inst. Oswaldo Cruz 1998, 93:663-668.
11. Decuypere S., Vanaerschot M., Rijal S., Yardley V., Maes L., De Doncker S., Chappuis F., Dujardin J.C. Gene expression profiling of Leishmania (Leishmania) donovani: overcoming technical variation and exploiting biological variation. Parasitology 2008, 135:183-194.
12. Denton H., McGregor J.C., Coombs G.H. Reduction of anti-leishmanial pentavalent antimonial drugs by a parasite-specific thiol-dependent reductase, TDR1. Biochem. J. 2004, 381:405-412.
13. Desjeux P. The increase in risk factors for leishmaniasis worldwide. Trans. R. Soc. Trop. Med. Hyg. 2001, 95:239-243.
14. El Fadili K., Messier N., Leprohon P., Roy G., Guimond C., Trudel N., Saravia N.G., Papadopoulou B., Legare D., Ouellette M. Role of the ABC transporter MRPA (PGPA) in antimony resistance in Leishmania infantum axenic and intracellular amastigotes. Antimicrob. Agents Chemother. 2005, 49:1988-1993.
15. Figarella K., Uzcategui N.L., Zhou Y., LeFurgey A., Ouellette M., Bhattacharjee H., Mukhopadhyay R. Biochemical characterization of Leishmania major aquaglyceroporin LmAQP1: possible role in volume regulation and osmotaxis. Mol. Microbiol. 2007, 65:1006-1017.
16. Gamboa D., Van Eys G., Victoir K., Torres K., Adaui V., Arevalo J., Dujardin J.C. Putative markers of infective life stages in Leishmania (Viannia) braziliensis. Parasitology 2007, 134:1689-1698.
17. Gourbal B., Sonuc N., Bhattacharjee H., Légaré D., Sundar S., Ouellette M., Rosen B.P., Mukhopadhyay R. Drug uptake and modulation of drug resistance in Leishmania by an aquaglyceroporin. J. Biol. Chem. 2004, 279:31010-31017.
18. Grimaldi G., Tesh R.B., McMahon-Pratt D. A review of the geographic distribution and epidemiology of leishmaniasis in the New World. Am. J. Trop. Med. Hyg. 1989, 41:687-725.
19. Grondin K., Haimeur A., Mukhopadhyay R., Rosen B.P., Ouellette M. Co-amplification of the gamma-glutamylcysteine synthetase gene gsh1 and of the ABC transporter gene pgpA in arsenite-resistant Leishmania tarentolae. EMBO J. 1997, 16:3057-3065.
20. Guimond C., Trudel N., Brochu C., Marquis N., El Fadili A., Peytavi R., Briand G., Richard D., Messier N., Papadopoulou B., Corbeil J., Bergeron M.G., Légaré D., Ouellette M. Modulation of gene expression in Leishmania drug resistant mutants as determined by targeted DNA microarrays. Nucleic Acids Res. 2003, 31:5886-5896.
21. Hadighi R., Mohebali M., Boucher P., Hajjaran H., Khamesipour A., Ouellette M. Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites. PLoS Med. 2006, 3:e162.
22. Haimeur A., Brochu C., Genest P., Papadopoulou B., Ouellette M. Amplification of the ABC transporter gene PGPA and increased trypanothione levels in potassium antimonyl tartrate (Sb(III)) resistant Leishmania tarentolae. Mol. Biochem. Parasitol. 2000, 108:131-135.
23. Lainson R., Shaw J.J. Evolution, classification and geographical distribution. The Leishmaniasis in Biology and Epidemiology 1987, 1-120. Academic Press, London. W. Peters, R. Killick-Kendrick (Eds.).
24. Lainson R., Shaw J.J., Silveira F.T., de Souza A.A., Braga R.R., Ishikawa E.A. The dermal leishmaniases of Brazil, with special reference to the eco-epidemiology of the disease in Amazonia. Mem. Inst. Oswaldo Cruz 1994, 89:435-443.
25. Lira R., Sunder S., Makharia A., Kenney R., Gam A., Saraiva E., Sack D. Evidence that high incidence of treatment failure in Indian kala-azar is due to the emergence of antimony resistant strains of Leishmania donovani. J. Infect. Dis. 1999, 180:564-567.
26. Maharjan M., Singh S., Chatterjee M., Madhubala R. Role of aquaglyceroporin (AQP1) gene and drug uptake in antimony-resistant clinical isolates of Leishmania donovani. Am. J. Trop. Med. Hyg. 2008, 79:69-75.
27. Marquis N., Gourbal B., Rosen B.P., Mukhopadhyay R., Ouellette M. Modulation in aquaglyceroporin AQP1 gene transcript levels in drug-resistant Leishmania. Mol. Microbiol. 2005, 57:1690-1699.
28. McCarthy D.J., Smyth G.K. Testing significance relative to a fold-change threshold is a TREAT. Bioinformatics 2009, 25:765-771.
29. Mukherjee A., Padmanabhan P.K., Singh S., Roy G., Girard I., Chatterjee M., Ouellette M., Madhubala R. Role of ABC transporter MRPA, γ-glutamylcysteine synthetase and ornithine decarboxylase in natural antimony-resistant isolates of Leishmania donovani. J. Antimicrob. Chemother. 2007, 59:204-211.
30. Neafsey D.E., Schaffner S.F., Volkman S.K., Park D., Montgomery P., Milner D.A., Lukens A., Rosen D., Daniels R., Houde N., Cortese J.F., Tyndall E., Gates C., Stange-Thomann N., Sarr O., Ndiaye D., Ndir O., Mboup S., Ferreira M.U., Moraes S.D., Dash A.P., Chitnis C.E., Wiegand R.C., Hartl D.L., Birren B.W., Lander E.S., Sabeti P.C., Wirth D.F. Genome-wide SNP genotyping highlights the role of natural selection in Plasmodium falciparum population divergence. Genome Biol. 2008, 9:R171.
31. Oliveira-Neto M.P., Schubach A., Mattos M., Gonçalves-Costa S.C., Pirmez C. A low-dose antimony treatment in 159 patients with American cutaneous leishmaniasis: extensive follow-up studies (up to 10 years). Am. J. Trop. Med. Hyg. 1997, 57:651-655.
32. Palacios R., Osorio L.E., Grajalew L.F., Ochoa M.T. Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania Viannia species. Am. J. Trop. Med. Hyg. 2001, 64:187-193.
33. Peacock C.S., Seeger K., Harris D., Murphy L., Ruiz J.C., Quail M.A., Peters N., Adlem E., Tivey A., Aslett M., Kerhornou A., Ivens A., Fraser A., Rajandream M.A., Carver T., Norbertczak H., Chillingworth T., Hance Z., Jagels K., Moule S., Ormond D., Rutter S., Squares R., Whitehead S., Rabbinowitsch E., Arrowsmith C., White B., Thurston S., Bringaud F., Baldauf S.L., Faulconbridge A., Jeffares D., Depledge D.P., Oyola S.O., Hilley J.D., Brito L.O., Tosi L.R., Barrell B., Cruz A.K., Mottram J.C., Smith D.F., Berriman M. Comparative genomic analysis of three Leishmania species that cause diverse human disease. Nat. Genet. 2007, 39:839-847.
34. Rebrikov D.V., Trofimov D.Yu. Real-time PCR: a review of approaches to data analysis. Prikl. Biokhim. Mikrobiol. 2006, 42:520-528.
35. Rijal S., Yardley V., Chappuis F., Decuypere S., Khanal B., Singh R., Boelaert M., De Doncker S., Croft S., Dujardin J.C. Antimonial treatment of visceral leishmaniasis: are current in vitro susceptibility assays adequate for prognosis of in vivo therapy outcome?. Microbes Infect. 2007, 9:529-535.
36. Ritz C., Spiess A.N. qpcR: an R package for sigmoidal model selection in quantitative real-time polymerase chain reaction analysis. Bioinformatics 2008, 24:1549-1551.
37. Rochette A., Raymond F., Ubeda J.M., Smith M., Messier N., Boisvert S., Rigault P., Corbeil J., Ouellette M., Papadopoulou B. Genome-wide gene expression profiling analysis of Leishmania major and Leishmania infantum developmental stages reveals substantial differences between the two species. BMC Genomics 2008, 9:255.
38. Romero G.A., Guerra M.V.F., Paes M.G., Macêdo V.O. Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniate. Am. J. Trop. Med. Hyg. 2001, 65:456-465.
39. Saxena A., Lahav T., Holland N., Aggarwal G., Anupama A., Huang Y., Volpin H., Myler P.J., Zilberstein D. Analysis of the Leishmania donovani transcriptome reveals an ordered progression of transient and permanent changes in gene expression during differentiation. Mol. Biochem. Parasitol. 2007, 152:53-65.
40. Shaw J.J., De Faria D.L., Basano S.A., Corbett C.E., Rodrigues C.J., Ishikawa E.A., Camargo L.M. The aetiological agents of American cutaneous leishmaniasis in the municipality of Monte Negro, Rondônia state, western Amazonia, Brazil. Ann. Trop. Med. Parasitol. 2007, 101:681-688.
41. Spiess A.N., Feig C., Ritz C. Highly accurate sigmoidal fitting of real-time PCR data by introducing a parameter for asymmetry. BMC Bioinform. 2008, 9:221.
42. Teixeira A.C., Paes M.G., Guerra J.O., Prata A., Silva-Vergara M.L. Failure of both azithromycin and antimony to treat cutaneous leishmaniasis in Manaus, AM, Brazil. Rev. Inst. Med. Trop. Sao Paulo 2008, 50:157-160.
43. Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., Speleman A. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002, 3. RESEARCH0034.
44. Vermeersch M., da Luz R.I., Toté K., Timmermans J.P., Cos P., Maes L. In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences. Antimicrob. Agents Chemother. 2009, 53:3855-3859.
45. Wyllie S., Cunningham M.L., Fairlamb A.H. Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani. J. Biol. Chem. 2004, 279:39925-39932.
46. Yardley V., Ortuno N., Llanos-Cuentas A., Chappuis F., De Doncker S., Ramirez L., Croft S., Arevalo J., Adaui V., Bermudez H., Decuypere S., Dujardin J.C. American tegumentary leishmaniasis: is antimonial treatment outcome related to parasite drug susceptibility?. J. Infect. Dis. 2006, 194:1168-1175.